London UK, 7th April 2014: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that it has been chosen to participate in the Technology Strategy Board’s (TSB) showcase at this year’s BioTrinity European Biopartnering and Investment Conference in London (12-14 May 2014).
Organised by OBN, the BioTrinity conference is a leading European partnering forum bringing together R&D companies with big pharma and biomedical investors. Dr Salman Rahman, CEO and co-founder of Vasgen said: “We are very pleased to have been selected to be part of the TSB’s showcase at BioTrinity 2014. This is a great opportunity for Vasgen to meet potential future partners and investors who may work with us to develop our therapeutic programmes and platform technology for further drug discovery.”
-Ends-
Notes to Editors
Vasgen
Vasgen limited is a new London-based biotech company developing innovative ocular and cancer therapeutics to meet unmet clinical needs. The Company’s technologies include AbIMP®, a novel antibody-based approach allowing development of highly selective inhibitors of metzincin metalloproteinases with a particular focus on the ADAMs gene family of sheddases. The Company’s lead product under development is a pre-clinical stage therapeutic AbIMP targeting ADAM15 for anti-angiogenesis therapy. More information is available at www.vasgen.co.uk
For further information please contact:
Tel : +44 (0)207 691 2149
info@vasgen.co.uk
Technology Strategy Board
The Technology Strategy Board is the UK’s innovation agency. It’s goal is to accelerate economic growth by stimulating and supporting business-led innovation. More information is available at www.innovateuk.org